Anthera appoints Bogdan Dziurzynski to board
This article was originally published in Scrip
Anthera Pharmaceuticals, a biopharmaceutical company developing products to treat serious diseases associated with inflammation, has appointed Dr Bogdan Dziurzynski to its board of directors. Dr Dziurzynski currently serves as a strategic regulatory management consultant to the biotech industry. He is on the boards of Dendreon and the Biologics Consulting Group, and the advisory board of Integrated Biotherapeutics. Previously, Dr Dziurzynski served as chair and president of the Regulatory Affairs Professional Society, and senior vice-president of regulatory affairs and quality assurance for MedImmune.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.